BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31758441)

  • 1. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.
    Hemmersbach-Miller M; Alexander BD; Pieper CF; Schmader KE
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):455-463. PubMed ID: 31758441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
    J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
    Chitasombat MN; Watcharananan SP
    F1000Res; 2018; 7():1568. PubMed ID: 30473779
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
    McGuirk M; Shahzad M; Amin MK; Khan MA; Bellman P; Mudaranthakam DP; DeJarnette S; Lutfi F; Ahmed N; Bansal R; Abdelhakim H; Gorsline C; Shoemaker DM; Abdallah AO; Shune L; Abhyankar SH; Singh AK; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2024 Jun; 84():102039. PubMed ID: 38513813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
    Schlott F; Steubl D; Hoffmann D; Matevossian E; Lutz J; Heemann U; Hösel V; Busch DH; Renders L; Neuenhahn M
    PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D; Hafferty J; Fulton L; Friend P; Devaney A; Loke J; Welsh KI; Handa A; Klenerman P
    J Clin Virol; 2008 Feb; 41(2):92-5. PubMed ID: 18032098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.
    Beck JC; Wagner JE; DeFor TE; Brunstein CG; Schleiss MR; Young JA; Weisdorf DH; Cooley S; Miller JS; Verneris MR
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):215-22. PubMed ID: 19786112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses.
    Toupance O; Bouedjoro-Camus MC; Carquin J; Novella JL; Lavaud S; Wynckel A; Jolly D; Chanard J
    Transpl Int; 2000; 13(6):413-9. PubMed ID: 11140239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.
    Maggi F; Focosi D; Statzu M; Bianco G; Costa C; Macera L; Spezia PG; Medici C; Albert E; Navarro D; Scagnolari C; Pistello M; Cavallo R; Antonelli G
    Sci Rep; 2018 Oct; 8(1):15490. PubMed ID: 30341363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV Viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation.
    Elfadawy N; Flechner SM; Liu X; Schold J; Srinivas TR; Poggio E; Fatica R; Avery R; Mossad SB
    Transplantation; 2013 Dec; 96(12):1097-103. PubMed ID: 24056621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
    Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
    Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.